Doctor

Ever-increasing attention and research efforts.

Rare diseases are undoubtedly a major challenge for the health systems of all developed countries, even those with welfare and healthcare systems......

New steps in the training of young ophthalmologists

Phacoemulsification and intraocular lenses (IOLs) marked a revolution in cataract surgery several decades ago: in 1967 Charles D. Kelman performed the first phacoemulsification, while Harold......

Molecular editing to obtain biocompatible organs and tissues from animals.

The gap between the waiting lists of those in need of an organ and the number of organs actually available for transplantation is still very large and threatens to......

Promising results and limited side effects.

At the 33rd ASRS (American Society of Retina Specialists) Congress, Vienna 10-14 July 2015, data from a long-term study were presented, showing a good profile of......

Innovative technologies for cataract refractive surgery.
The development of new IOLs is in progress and some hi-tech IOLs are already undergoing clinical trials to strike the more and more challenging goals of contemporary cataract surgery.

The development of new IOLs is in progress and some hi-tech IOLs are already undergoing clinical trials to strike the more and more challenging goals of contemporary cataract surgery. The......

Size and location decisive in treatment outcome

Retinal haemangioblastoma is a rare disease that is difficult to manage, involving a careful assessment of the balance between potential visual loss caused by the tumour vs visual loss induced by therapeutic treatments. When......

Insufficient pupillary dilation with normal mydriatic drugs can be caused by pathological or paraphysiological precedents in the iris; the most frequent are the presence of posterior synechiae (due to previous uveitic facts or previous surgery or prolonged use of myotics) and atrophy and sclerosis of the iris stroma and pupillary sphincter (capsular pseudoexfoliation syndrome or due to tissue senescence facts alone).

A new association between poor mydriasis and the use of tamsulosin (Pradifâ, Omnicâ), an a-1A receptor blocker, has recently been described (1). This drug is used to treat patients with......

Idiopathic sub-retinal neovascularisations In subjects under 50 years of age, the finding of a sub-retinal neovascular membrane (CNV) should promote investigations to exclude associated causes, first......